Sponsors (27)
The bill expands Medicare drug negotiation to more medicines, which should lower costs for beneficiaries and the program, but narrows eligibility windows and caps price reductions in ways that could limit savings and adds administrative burden that may delay benefits.
Medicare beneficiaries will likely pay lower prices for more medicines because the bill expands negotiation to up to 50 drugs starting in 2028, increasing the chance high-cost drugs are negotiated and reducing out-of-pocket and Part D costs for many enrollees.
Taxpayers and the Medicare program may see reduced federal drug spending because negotiating a larger pool of drugs increases the potential for overall program savings and lower federal outlays.
Medicare beneficiaries (especially people with recently approved or single-source drugs) may face delayed price reductions because the bill shortens exclusivity lookback periods, making fewer newly marketed drugs eligible for negotiation.
Medicare beneficiaries and taxpayers may realize smaller-than-expected savings because lowering the maximum fair price ceilings for certain categories (to 76/55/30%) caps how much negotiated prices can drop for some drugs.
Federal employees at HHS and the program could face increased administrative workload and resource needs as negotiating up to 50 drugs raises implementation complexity and could risk delays in rolling out negotiations in 2028.
Based on analysis of 2 sections of legislative text.
Expands and accelerates Medicare drug price negotiation: raises 2028 targets to 50 drugs, shortens exclusivity lookback windows, and lowers statutory price ceilings.
Official title: Amend title XVIII of the Social Security Act to strengthen the drug pricing reforms in the Inflation Reduction Act.
Introduced May 21, 2025 by Amy Klobuchar · Last progress May 21, 2025
Amends the Medicare Drug Price Negotiation Program to speed up and broaden federal negotiation of drug prices starting with the 2028 price year. It raises the number of drugs subject to negotiation from 15 to 50 (applying to 2028 or a later year), shortens statutory lookback windows that determine single-source exclusivity from 7/11 years to 3 years, and lowers the maximum fair price ceilings used to set negotiated prices.